145 related articles for article (PubMed ID: 17419693)
21. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
[TBL] [Abstract][Full Text] [Related]
22. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.
Bloor AJ; Thomson K; Chowdhry N; Verfuerth S; Ings SJ; Chakraverty R; Linch DC; Goldstone AH; Peggs KS; Mackinnon S
Biol Blood Marrow Transplant; 2008 Jan; 14(1):50-8. PubMed ID: 18158961
[TBL] [Abstract][Full Text] [Related]
23. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
[TBL] [Abstract][Full Text] [Related]
24. The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft-versus-host disease.
Kim SY; Lee DG; Kim MS; Kim HJ; Lee S; Min CK
Am J Hematol; 2008 Oct; 83(10):784-8. PubMed ID: 18661492
[TBL] [Abstract][Full Text] [Related]
25. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A
Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
27. Successful treatment of refractory joint contractures caused by sclerodermatous graft versus host disease.
Kim JB; Liakopoulou E; Watson JS
J Plast Reconstr Aesthet Surg; 2008 Oct; 61(10):1235-8. PubMed ID: 17509955
[TBL] [Abstract][Full Text] [Related]
28. Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA.
Lawler M; McCann SR; Marsh JC; Ljungman P; Hows J; Vandenberghe E; O'Riordan J; Locasciulli A; Socié G; Kelly A; Schrezenmeier H; Marin P; Tichelli A; Passweg JR; Dickenson A; Ryan J; Bacigalupo A;
Br J Haematol; 2009 Mar; 144(6):933-45. PubMed ID: 19183198
[TBL] [Abstract][Full Text] [Related]
29. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease.
van Burik JA; Carter SL; Freifeld AG; High KP; Godder KT; Papanicolaou GA; Mendizabal AM; Wagner JE; Yanovich S; Kernan NA
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1487-98. PubMed ID: 18022579
[TBL] [Abstract][Full Text] [Related]
30. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells.
Trzonkowski P; Bieniaszewska M; Juścińska J; Dobyszuk A; Krzystyniak A; Marek N; Myśliwska J; Hellmann A
Clin Immunol; 2009 Oct; 133(1):22-6. PubMed ID: 19559653
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic stem cell transplantation after reduced-intensity conditioning for acute myeloid leukaemia: impact of chronic graft-versus-host disease.
Valcárcel D; Martino R; Piñana JL; Sierra J
Curr Opin Oncol; 2009 Jun; 21 Suppl 1():S35-7. PubMed ID: 19561412
[TBL] [Abstract][Full Text] [Related]
32. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
33. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
34. B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment-related mortality of allogeneic peripheral blood stem cell transplantation.
Iori AP; Torelli GF; De Propris MS; Milano F; Pupella S; Gozzer M; Mancini F; Milani ML; Intoppa S; Cerretti R; Lucarelli B; Valle V; Malandruccolo L; Iannella E; Arleo E; Guarini A; Foà R
Transplantation; 2008 Feb; 85(3):386-90. PubMed ID: 18322430
[TBL] [Abstract][Full Text] [Related]
35. Annular plaques: An unusual manifestation of graft-versus-host disease.
Alexander LJ; Paravar T; Duvic M; Prieto V; Hymes SR
Dermatol Online J; 2012 Jun; 18(6):4. PubMed ID: 22747928
[TBL] [Abstract][Full Text] [Related]
36. [Sclerodermiform chronic graft-versus-host disease after allogenic peripheral blood stem-cell transplantation].
Neid T; Danz B; Eismann R; Bramsiepe I; Wohlrab J; Marsch WC; Fiedler E
Dtsch Med Wochenschr; 2009 May; 134(21):1106-9. PubMed ID: 19437374
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD.
Magro L; Catteau B; Coiteux V; Bruno B; Jouet JP; Yakoub-Agha I
Bone Marrow Transplant; 2008 Dec; 42(11):757-60. PubMed ID: 18762765
[TBL] [Abstract][Full Text] [Related]
38. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation.
Godder KT; Henslee-Downey PJ; Mehta J; Park BS; Chiang KY; Abhyankar S; Lamb LS
Bone Marrow Transplant; 2007 Jun; 39(12):751-7. PubMed ID: 17450185
[TBL] [Abstract][Full Text] [Related]
39. Post-transplant infections: single center experience from the developing world.
Ullah K; Raza S; Ahmed P; Chaudhry QU; Satti TM; Ahmed S; Mirza SH; Akhtar F; Kamal K; Akhtar FM
Int J Infect Dis; 2008 Mar; 12(2):203-14. PubMed ID: 17920999
[TBL] [Abstract][Full Text] [Related]
40. Bone marrow transplantation: new approaches to immunosuppression and management of acute graft-versus-host disease.
Auletta JJ; Cooke KR
Curr Opin Pediatr; 2009 Feb; 21(1):30-8. PubMed ID: 19242239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]